Denmark
· Delayed Price · Currency is DKK Zealand Pharma Statistics
Total Valuation
Zealand Pharma has a market cap or net worth of DKK 62.88 billion. The enterprise value is 53.53 billion.
| Market Cap | 62.88B |
| Enterprise Value | 53.53B |
Important Dates
The next estimated earnings date is Thursday, November 7, 2024.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Zealand Pharma has 70.94 million shares outstanding. The number of shares has increased by 16.42% in one year.
| Shares Outstanding | 70.94M |
| Shares Change (YoY) | +16.42% |
| Shares Change (QoQ) | +1.72% |
| Owned by Insiders (%) | 0.32% |
| Owned by Institutions (%) | 47.57% |
| Float | 60.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 145.15 |
| PB Ratio | 6.69 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -75.18 |
| EV / Sales | 145.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -102.08 |
Financial Position
The company has a current ratio of 35.57, with a Debt / Equity ratio of 4.15.
| Current Ratio | 35.57 |
| Quick Ratio | 35.20 |
| Debt / Equity | 4.15 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.74 |
| Interest Coverage | -33.62 |
Financial Efficiency
Return on equity (ROE) is -12.80% and return on invested capital (ROIC) is -7.75%.
| Return on Equity (ROE) | -12.80% |
| Return on Assets (ROA) | -7.38% |
| Return on Capital (ROIC) | -7.75% |
| Revenue Per Employee | 1.28M |
| Profits Per Employee | -2.47M |
| Employee Count | 253 |
| Asset Turnover | 0.06 |
| Inventory Turnover | 104.86 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +239.40% in the last 52 weeks. The beta is 0.64, so Zealand Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.64 |
| 52-Week Price Change | +239.40% |
| 50-Day Moving Average | 894.84 |
| 200-Day Moving Average | 619.16 |
| Relative Strength Index (RSI) | 51.39 |
| Average Volume (20 Days) | 385,555 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Zealand Pharma had revenue of DKK 367.97 million and -712.00 million in losses. Loss per share was -11.82.
| Revenue | 367.97M |
| Gross Profit | -346.47M |
| Operating Income | -720.72M |
| Pretax Income | -716.56M |
| Net Income | -712.00M |
| EBITDA | -713.21M |
| EBIT | -720.72M |
| Loss Per Share | -11.82 |
Balance Sheet
The company has 8.93 billion in cash and 389.99 million in debt, giving a net cash position of 9.36 billion or 131.92 per share.
| Cash & Cash Equivalents | 8.93B |
| Total Debt | 389.99M |
| Net Cash | 9.36B |
| Net Cash Per Share | 131.92 |
| Equity (Book Value) | 9.40B |
| Book Value Per Share | 132.48 |
| Working Capital | 8.89B |
Cash Flow
In the last 12 months, operating cash flow was -508.19 million and capital expenditures -16.18 million, giving a free cash flow of -524.37 million.
| Operating Cash Flow | -508.19M |
| Capital Expenditures | -16.18M |
| Free Cash Flow | -524.37M |
| FCF Per Share | -7.39 |
Margins
Gross margin is -94.16%, with operating and profit margins of -195.86% and -193.49%.
| Gross Margin | -94.16% |
| Operating Margin | -195.86% |
| Pretax Margin | -194.73% |
| Profit Margin | -193.49% |
| EBITDA Margin | -193.82% |
| EBIT Margin | -195.86% |
| FCF Margin | -142.50% |
Dividends & Yields
Zealand Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.42% |
| Shareholder Yield | -16.42% |
| Earnings Yield | -1.33% |
| FCF Yield | -0.83% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |